Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [F]FDG PET/CT.

Abstract

Authors

• Clemens P Spielvogel
  Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
• Aleksa Lazarevic
  Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
• Lucia Zisser
  Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
• David Haberl
  Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
• Christophoros Eseroglou
  Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Spitalgasse 23, Vienna, A-1090, Austria.
• Lucian Beer
  Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge CB2 0RE, UK; Department of Biomedical Imaging and Image-guided Therapy, Medical University Vienna, Vienna 1090, Austria. Electronic address: lb795@cam.ac.uk.
• Marcus Hacker
  Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
• Raffaella Calabretta
  Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Spitalgasse 23, Vienna, 1090, Austria.

Keywords

No keywords available for this article.

External Resources